Clinical trial
Phase 4, Randomized, Placebo-controlled, Cross-over Trial to Assess the Effect of 4-week Ertugliflozin (SGLT-2 Inhibitor) Therapy on Renal Oxygenation by BOLD-MRI and Renal Oxygen Consumption by PET Using ¹¹C-acetate in T2DM Without Kidney Disease and Healthy Controls.
NCT04027530 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 4, Randomized, Placebo-controlled, Cross-over Trial to Assess the Effect of 4-week Ertugliflozin (SGLT-2 Inhibitor) Therapy on Renal Oxygenation by BOLD-MRI and Renal Oxygen Consumption by PET Using ¹¹C-acetate in T2DM Without Kidney Disease and Healthy Controls.
- Lead sponsor
- Amsterdam UMC, location VUmc
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 10, 2020
- Completion date
- January 9, 2023
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diabetic kidney disease, diabetic nephropathy, ertugliflozin, renal hypoxia, renoprotection, sglt2 inhibitor, type 2 diabetes mellitus